Abstract
The peroxisome proliferator-activated receptor (PPAR) family of nuclear receptors, a set of three receptor sub-types encoded by distinct genes, function as lipid sensors to regulate a broad range of genes in many metabolically active tissues. Synthetic PPAR agonists have exhibited therapeutic benefits in treating diabetes and cardiovascular diseases. The discovery of PPAR-specific ligands has led to significant advancement in our understanding of the structure of these receptor proteins and the molecular mechanism of their ligand-dependent activation. Herein, we present both recent progress in the functional analysis of these orphan receptors and the confirmation of the PPARs as molecular targets for the development of new medicines to treat human metabolic disease.
Keywords: peroxisome proliferator, ppar, nuclear receptor, ppar agonists, ppar-specific
Current Medicinal Chemistry
Title: Recent Advances in Peroxisome Proliferator-Activated Receptor Science
Volume: 10 Issue: 4
Author(s): Barry G. Shearer and William J. Hoekstra
Affiliation:
Keywords: peroxisome proliferator, ppar, nuclear receptor, ppar agonists, ppar-specific
Abstract: The peroxisome proliferator-activated receptor (PPAR) family of nuclear receptors, a set of three receptor sub-types encoded by distinct genes, function as lipid sensors to regulate a broad range of genes in many metabolically active tissues. Synthetic PPAR agonists have exhibited therapeutic benefits in treating diabetes and cardiovascular diseases. The discovery of PPAR-specific ligands has led to significant advancement in our understanding of the structure of these receptor proteins and the molecular mechanism of their ligand-dependent activation. Herein, we present both recent progress in the functional analysis of these orphan receptors and the confirmation of the PPARs as molecular targets for the development of new medicines to treat human metabolic disease.
Export Options
About this article
Cite this article as:
Shearer G. Barry and Hoekstra J. William, Recent Advances in Peroxisome Proliferator-Activated Receptor Science, Current Medicinal Chemistry 2003; 10 (4) . https://dx.doi.org/10.2174/0929867033368295
DOI https://dx.doi.org/10.2174/0929867033368295 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hedgehog Target Genes: Mechanisms of Carcinogenesis Induced by Aberrant Hedgehog Signaling Activation
Current Molecular Medicine Recombinant Snake Venom Cystatin Inhibits Tumor Angiogenesis in vitro and in vivo Associated with Downregulation of VEGF-A165, Flt-1 and bFGF
Anti-Cancer Agents in Medicinal Chemistry Trafficking of Neuronal Two Pore Domain Potassium Channels
Current Neuropharmacology The TGF-β 1/Foxp3 Regulatory Axis in Immune Self-Tolerance: Implications for Health and Disease
Inflammation & Allergy - Drug Targets (Discontinued) Colon Cancer and Specific Ways to Deliver Drugs to the Large Intestine
Anti-Cancer Agents in Medicinal Chemistry Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis
Current Cancer Drug Targets Challenges and Opportunities for Clinical Research in the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs Synthesis and Anti-Proliferative Activity of New Biphenyle-Benzylidenethiazolidine- 2,4-dione Bis-Adducts Containing Various Heterocyclic Cores
Letters in Drug Design & Discovery Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets Meta-analysis Reveals No Association of DNMT3B -149 C>T Gene Polymorphism With Overall Cancer Risk
Current Genomics Edtorial [Hot topic: Glucocorticoids from Chemistry to Clinics (Executive Editor: Fortunato Vesce)]
Current Pharmaceutical Design Synthesis of Some Coumarinyl Chalcones and their Antiproliferative Activity Against Breast Cancer Cell Lines
Letters in Drug Design & Discovery Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Patent Selections
Recent Patents on Chemical Engineering In-Vitro CYP3A4, CYP2E1 and UGT Activity in Human Liver Microsomes by Strobilanthes crispus Leaf Extracts
The Natural Products Journal Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Actively Targeted Nanoparticles for Drug Delivery to Tumor
Current Drug Metabolism In Silico and Biochemical Analyses Identify Quinone Reductase 2 as a Target of Piceatannol
Current Medicinal Chemistry Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design